Free Trial

Genesis Healthcare (GEN) Stock Forecast & Price Target

Notice: This company has been marked as potentially delisted and may not be actively trading.

Genesis Healthcare - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Based on 5 Wall Street analysts who have issued ratings for Genesis Healthcare in the last 12 months, the stock has a consensus rating of "Hold." Out of the 5 analysts, 3 have given a hold rating, and 2 have given a buy rating for GEN.

Consensus Price Target

2.42% Upside
High Forecast$29.00
Average Forecast$26.20
Low Forecast$25.00

According to the 5 analysts' twelve-month price targets for Genesis Healthcare, the average price target is $26.20. The highest price target for GEN is $29.00, while the lowest price target for GEN is $25.00. The average price target represents a forecasted upside of 2.42% from the current price of $25.58.

TypeCurrent Forecast
7/18/23 to 7/17/24
1 Month Ago
6/18/23 to 6/17/24
3 Months Ago
4/19/23 to 4/18/24
1 Year Ago
7/18/22 to 7/18/23
Consensus Rating
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
2 Buy rating(s)
2 Buy rating(s)
3 Buy rating(s)
2 Buy rating(s)
3 Hold rating(s)
3 Hold rating(s)
2 Hold rating(s)
0 Hold rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$26.20$26.20$26.00$23.33
Forecasted Upside2.42% Upside12.59% Upside24.95% Upside38.61% Upside
Get Genesis Healthcare Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for GEN and its competitors with MarketBeat's FREE daily newsletter.

GEN Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

GEN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Genesis Healthcare Stock vs. The Competition

TypeGenesis HealthcareBusiness Services CompaniesS&P 500
Consensus Rating Score
Consensus RatingHoldModerate BuyModerate Buy
Predicted Upside2.42% Upside133.63% Upside7.63% Upside
News Sentiment RatingNeutral News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
6/7/2024Morgan Stanley
3 of 5 stars
 DowngradeOverweight ➝ Equal Weight$28.00 ➝ $27.00+6.13%
2 of 5 stars
 Boost TargetBuy ➝ Buy$26.00 ➝ $29.00+16.51%
2 of 5 stars
 DowngradeOverweight ➝ Equal Weight$28.00 ➝ $25.00+11.91%
2/2/2024Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingSector Perform ➝ Sector Perform$25.00+4.52%
11/16/2023Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$25.00+26.52%
5/19/2023Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$27.00+67.49%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 10:25 AM ET.

GEN Forecast - Frequently Asked Questions

What is Genesis Healthcare's forecast for 2024?

According to the research reports of 5 Wall Street equities research analysts, the average twelve-month stock price forecast for Genesis Healthcare is $26.20, with a high forecast of $29.00 and a low forecast of $25.00.

Should I buy or sell Genesis Healthcare stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Genesis Healthcare in the last year. There are currently 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" GEN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GEN, but not buy additional shares or sell existing shares.

Does Genesis Healthcare's stock price have much upside?

According to analysts, Genesis Healthcare's stock has a predicted upside of 12.59% based on their 12-month stock forecasts.

Has Genesis Healthcare been downgraded by Wall Street analysts recently?

Over the previous 90 days, Genesis Healthcare's stock had 1 downgrade by analysts.

What analysts cover Genesis Healthcare?

Genesis Healthcare has been rated by research analysts at Argus, and Morgan Stanley in the past 90 days.

Do Wall Street analysts like Genesis Healthcare more than its competitors?

Analysts like Genesis Healthcare less than other "business services" companies. The consensus rating for Genesis Healthcare is Hold while the average consensus rating for "business services" companies is Moderate Buy. Learn more on how GEN compares to other companies.

This page (NYSE:GEN) was last updated on 7/17/2024 by Staff

From Our Partners